nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—ADRA1B—polycystic ovary syndrome	0.44	0.598	CbGaD
Loxapine—ADRA1A—polycystic ovary syndrome	0.296	0.402	CbGaD
Loxapine—HTR2A—urine—polycystic ovary syndrome	0.000787	0.0584	CbGeAlD
Loxapine—Asenapine—ADRA1A—polycystic ovary syndrome	0.000678	0.118	CrCbGaD
Loxapine—Azelastine—ADRA1B—polycystic ovary syndrome	0.000652	0.113	CrCbGaD
Loxapine—HTR1E—female gonad—polycystic ovary syndrome	0.000617	0.0458	CbGeAlD
Loxapine—Olanzapine—ADRA1B—polycystic ovary syndrome	0.00056	0.0975	CrCbGaD
Loxapine—Chest discomfort—Metformin—polycystic ovary syndrome	0.000525	0.0793	CcSEcCtD
Loxapine—HRH2—adrenal gland—polycystic ovary syndrome	0.000475	0.0352	CbGeAlD
Loxapine—DRD5—female gonad—polycystic ovary syndrome	0.000471	0.035	CbGeAlD
Loxapine—DRD5—endocrine gland—polycystic ovary syndrome	0.000438	0.0325	CbGeAlD
Loxapine—Lightheadedness—Metformin—polycystic ovary syndrome	0.000415	0.0628	CcSEcCtD
Loxapine—HRH2—endocrine gland—polycystic ovary syndrome	0.000412	0.0306	CbGeAlD
Loxapine—Asenapine—ADRB2—polycystic ovary syndrome	0.000403	0.0701	CrCbGaD
Loxapine—Quetiapine—ADRA1D—polycystic ovary syndrome	0.000398	0.0693	CrCbGaD
Loxapine—Zuclopenthixol—ADRA1A—polycystic ovary syndrome	0.000396	0.0689	CrCbGaD
Loxapine—Olanzapine—ADRA1A—polycystic ovary syndrome	0.000377	0.0656	CrCbGaD
Loxapine—Nasal congestion—Metformin—polycystic ovary syndrome	0.00037	0.0559	CcSEcCtD
Loxapine—Trazodone—ADRA1A—polycystic ovary syndrome	0.000364	0.0634	CrCbGaD
Loxapine—Quetiapine—ADRA1B—polycystic ovary syndrome	0.00034	0.0591	CrCbGaD
Loxapine—ADRB1—adipose tissue—polycystic ovary syndrome	0.000328	0.0244	CbGeAlD
Loxapine—ADRA2C—adrenal cortex—polycystic ovary syndrome	0.000307	0.0228	CbGeAlD
Loxapine—Amoxapine—ADRA1A—polycystic ovary syndrome	0.0003	0.0522	CrCbGaD
Loxapine—Clozapine—ADRA1B—polycystic ovary syndrome	0.000292	0.0509	CrCbGaD
Loxapine—CHRM3—adipose tissue—polycystic ovary syndrome	0.000283	0.021	CbGeAlD
Loxapine—ADRA2C—endometrium—polycystic ovary syndrome	0.000274	0.0204	CbGeAlD
Loxapine—HTR1B—endocrine gland—polycystic ovary syndrome	0.000271	0.0201	CbGeAlD
Loxapine—CHRM2—endocrine gland—polycystic ovary syndrome	0.00027	0.02	CbGeAlD
Loxapine—Drowsiness—Metformin—polycystic ovary syndrome	0.00026	0.0392	CcSEcCtD
Loxapine—ADRA1A—adipose tissue—polycystic ovary syndrome	0.00026	0.0193	CbGeAlD
Loxapine—DRD2—pituitary gland—polycystic ovary syndrome	0.000255	0.019	CbGeAlD
Loxapine—ADRB1—endocrine gland—polycystic ovary syndrome	0.000255	0.0189	CbGeAlD
Loxapine—HTR2A—embryo—polycystic ovary syndrome	0.000254	0.0189	CbGeAlD
Loxapine—ADRA2C—uterus—polycystic ovary syndrome	0.000253	0.0188	CbGeAlD
Loxapine—HTR1A—adrenal gland—polycystic ovary syndrome	0.000253	0.0187	CbGeAlD
Loxapine—SLC6A2—adrenal gland—polycystic ovary syndrome	0.00025	0.0186	CbGeAlD
Loxapine—ADRA2C—pituitary gland—polycystic ovary syndrome	0.000248	0.0184	CbGeAlD
Loxapine—ADRA2C—adipose tissue—polycystic ovary syndrome	0.000247	0.0184	CbGeAlD
Loxapine—SLC6A4—endocrine gland—polycystic ovary syndrome	0.000247	0.0183	CbGeAlD
Loxapine—CHRM1—endocrine gland—polycystic ovary syndrome	0.000246	0.0182	CbGeAlD
Loxapine—HTR7—adrenal gland—polycystic ovary syndrome	0.000241	0.0179	CbGeAlD
Loxapine—CHRM3—female gonad—polycystic ovary syndrome	0.000236	0.0175	CbGeAlD
Loxapine—Trifluoperazine—ADRA1A—polycystic ovary syndrome	0.000236	0.041	CrCbGaD
Loxapine—Hepatitis—Metformin—polycystic ovary syndrome	0.000233	0.0352	CcSEcCtD
Loxapine—ADRA1A—adrenal gland—polycystic ovary syndrome	0.000233	0.0173	CbGeAlD
Loxapine—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.000232	0.0351	CcSEcCtD
Loxapine—Quetiapine—ADRA1A—polycystic ovary syndrome	0.000229	0.0398	CrCbGaD
Loxapine—Azelastine—CYP1A1—polycystic ovary syndrome	0.000224	0.039	CrCbGaD
Loxapine—HRH1—endometrium—polycystic ovary syndrome	0.000223	0.0165	CbGeAlD
Loxapine—ADRA2C—adrenal gland—polycystic ovary syndrome	0.000222	0.0165	CbGeAlD
Loxapine—CHRM3—endocrine gland—polycystic ovary syndrome	0.00022	0.0163	CbGeAlD
Loxapine—HTR1A—endocrine gland—polycystic ovary syndrome	0.000219	0.0163	CbGeAlD
Loxapine—ADRA2A—endometrium—polycystic ovary syndrome	0.000219	0.0162	CbGeAlD
Loxapine—SLC6A2—endocrine gland—polycystic ovary syndrome	0.000217	0.0161	CbGeAlD
Loxapine—Angiopathy—Metformin—polycystic ovary syndrome	0.000212	0.032	CcSEcCtD
Loxapine—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00021	0.0318	CcSEcCtD
Loxapine—HTR7—endocrine gland—polycystic ovary syndrome	0.000209	0.0155	CbGeAlD
Loxapine—ADRA2C—female gonad—polycystic ovary syndrome	0.000207	0.0154	CbGeAlD
Loxapine—ADRA2C—vagina—polycystic ovary syndrome	0.000206	0.0153	CbGeAlD
Loxapine—ADRA1A—endocrine gland—polycystic ovary syndrome	0.000202	0.015	CbGeAlD
Loxapine—ADRA2A—uterus—polycystic ovary syndrome	0.000202	0.015	CbGeAlD
Loxapine—HRH1—adipose tissue—polycystic ovary syndrome	0.000201	0.0149	CbGeAlD
Loxapine—Dysgeusia—Metformin—polycystic ovary syndrome	0.000199	0.03	CcSEcCtD
Loxapine—ADRA2A—pituitary gland—polycystic ovary syndrome	0.000198	0.0147	CbGeAlD
Loxapine—DRD2—endocrine gland—polycystic ovary syndrome	0.000198	0.0147	CbGeAlD
Loxapine—ADRA2A—adipose tissue—polycystic ovary syndrome	0.000197	0.0146	CbGeAlD
Loxapine—Clozapine—ADRA1A—polycystic ovary syndrome	0.000197	0.0342	CrCbGaD
Loxapine—Muscle spasms—Metformin—polycystic ovary syndrome	0.000195	0.0295	CcSEcCtD
Loxapine—Vision blurred—Metformin—polycystic ovary syndrome	0.000191	0.0289	CcSEcCtD
Loxapine—Tremor—Metformin—polycystic ovary syndrome	0.00019	0.0287	CcSEcCtD
Loxapine—Syncope—Metformin—polycystic ovary syndrome	0.000182	0.0275	CcSEcCtD
Loxapine—HRH1—adrenal gland—polycystic ovary syndrome	0.00018	0.0134	CbGeAlD
Loxapine—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000178	0.027	CcSEcCtD
Loxapine—ADRA2A—adrenal gland—polycystic ovary syndrome	0.000177	0.0131	CbGeAlD
Loxapine—Hypertension—Metformin—polycystic ovary syndrome	0.000175	0.0265	CcSEcCtD
Loxapine—Chest pain—Metformin—polycystic ovary syndrome	0.000173	0.0261	CcSEcCtD
Loxapine—HTR2A—pituitary gland—polycystic ovary syndrome	0.000168	0.0125	CbGeAlD
Loxapine—HRH1—female gonad—polycystic ovary syndrome	0.000168	0.0125	CbGeAlD
Loxapine—HRH1—vagina—polycystic ovary syndrome	0.000167	0.0124	CbGeAlD
Loxapine—Oedema—Metformin—polycystic ovary syndrome	0.000166	0.025	CcSEcCtD
Loxapine—ADRA2A—female gonad—polycystic ovary syndrome	0.000165	0.0122	CbGeAlD
Loxapine—ADRA2A—vagina—polycystic ovary syndrome	0.000164	0.0122	CbGeAlD
Loxapine—Shock—Metformin—polycystic ovary syndrome	0.000163	0.0246	CcSEcCtD
Loxapine—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000162	0.0245	CcSEcCtD
Loxapine—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000162	0.0245	CcSEcCtD
Loxapine—HRH1—endocrine gland—polycystic ovary syndrome	0.000156	0.0116	CbGeAlD
Loxapine—Hypotension—Metformin—polycystic ovary syndrome	0.000155	0.0234	CcSEcCtD
Loxapine—ADRA2A—endocrine gland—polycystic ovary syndrome	0.000153	0.0114	CbGeAlD
Loxapine—HTR2A—adrenal gland—polycystic ovary syndrome	0.000151	0.0112	CbGeAlD
Loxapine—Paraesthesia—Metformin—polycystic ovary syndrome	0.000149	0.0225	CcSEcCtD
Loxapine—Dyspnoea—Metformin—polycystic ovary syndrome	0.000148	0.0223	CcSEcCtD
Loxapine—Somnolence—Metformin—polycystic ovary syndrome	0.000147	0.0223	CcSEcCtD
Loxapine—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000143	0.0216	CcSEcCtD
Loxapine—Fatigue—Metformin—polycystic ovary syndrome	0.000143	0.0216	CcSEcCtD
Loxapine—Constipation—Metformin—polycystic ovary syndrome	0.000142	0.0214	CcSEcCtD
Loxapine—HTR2A—vagina—polycystic ovary syndrome	0.000139	0.0104	CbGeAlD
Loxapine—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000136	0.0206	CcSEcCtD
Loxapine—HTR2A—endocrine gland—polycystic ovary syndrome	0.000131	0.00969	CbGeAlD
Loxapine—Asthenia—Metformin—polycystic ovary syndrome	0.000119	0.018	CcSEcCtD
Loxapine—Pruritus—Metformin—polycystic ovary syndrome	0.000117	0.0177	CcSEcCtD
Loxapine—Dizziness—Metformin—polycystic ovary syndrome	0.00011	0.0166	CcSEcCtD
Loxapine—Vomiting—Metformin—polycystic ovary syndrome	0.000105	0.0159	CcSEcCtD
Loxapine—Rash—Metformin—polycystic ovary syndrome	0.000104	0.0158	CcSEcCtD
Loxapine—Dermatitis—Metformin—polycystic ovary syndrome	0.000104	0.0158	CcSEcCtD
Loxapine—Headache—Metformin—polycystic ovary syndrome	0.000104	0.0157	CcSEcCtD
Loxapine—Clozapine—CYP1A1—polycystic ovary syndrome	0.0001	0.0175	CrCbGaD
Loxapine—Nausea—Metformin—polycystic ovary syndrome	9.84e-05	0.0149	CcSEcCtD
Loxapine—CHRM5—Signaling Pathways—IRS1—polycystic ovary syndrome	3.81e-06	1.6e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—INS—polycystic ovary syndrome	3.81e-06	1.6e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IGF1—polycystic ovary syndrome	3.79e-06	1.59e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—AKT2—polycystic ovary syndrome	3.79e-06	1.59e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—CYP1A1—polycystic ovary syndrome	3.79e-06	1.59e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—GNAS—polycystic ovary syndrome	3.78e-06	1.59e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	3.78e-06	1.59e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—GNAS—polycystic ovary syndrome	3.77e-06	1.58e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IRS2—polycystic ovary syndrome	3.73e-06	1.57e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IGF1—polycystic ovary syndrome	3.73e-06	1.56e-05	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.73e-06	1.56e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.73e-06	1.56e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—AKT2—polycystic ovary syndrome	3.73e-06	1.56e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.71e-06	1.55e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.7e-06	1.55e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IRS2—polycystic ovary syndrome	3.7e-06	1.55e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IGF1—polycystic ovary syndrome	3.68e-06	1.54e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—AKT2—polycystic ovary syndrome	3.68e-06	1.54e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.68e-06	1.54e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.67e-06	1.54e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—POMC—polycystic ovary syndrome	3.66e-06	1.54e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.66e-06	1.54e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NRG1—polycystic ovary syndrome	3.66e-06	1.54e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—LEP—polycystic ovary syndrome	3.65e-06	1.53e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.65e-06	1.53e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—INS—polycystic ovary syndrome	3.64e-06	1.53e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.64e-06	1.53e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IRS1—polycystic ovary syndrome	3.63e-06	1.52e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—LEP—polycystic ovary syndrome	3.62e-06	1.52e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.6e-06	1.51e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NRG1—polycystic ovary syndrome	3.6e-06	1.51e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.6e-06	1.51e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NRG1—polycystic ovary syndrome	3.59e-06	1.51e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.59e-06	1.51e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NRG1—polycystic ovary syndrome	3.58e-06	1.5e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IRS1—polycystic ovary syndrome	3.58e-06	1.5e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NRG1—polycystic ovary syndrome	3.57e-06	1.5e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IRS2—polycystic ovary syndrome	3.57e-06	1.5e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IRS2—polycystic ovary syndrome	3.55e-06	1.49e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.54e-06	1.49e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NRG1—polycystic ovary syndrome	3.54e-06	1.48e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—MTHFR—polycystic ovary syndrome	3.53e-06	1.48e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NRG1—polycystic ovary syndrome	3.53e-06	1.48e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IGF1—polycystic ovary syndrome	3.52e-06	1.48e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—PPARG—polycystic ovary syndrome	3.52e-06	1.48e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—AKT2—polycystic ovary syndrome	3.52e-06	1.48e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	3.51e-06	1.47e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.5e-06	1.47e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—LEP—polycystic ovary syndrome	3.5e-06	1.47e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—POMC—polycystic ovary syndrome	3.49e-06	1.46e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—LEP—polycystic ovary syndrome	3.48e-06	1.46e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—POMC—polycystic ovary syndrome	3.47e-06	1.46e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—INS—polycystic ovary syndrome	3.47e-06	1.46e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IRS2—polycystic ovary syndrome	3.46e-06	1.45e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—INS—polycystic ovary syndrome	3.46e-06	1.45e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—POMC—polycystic ovary syndrome	3.45e-06	1.44e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—INS—polycystic ovary syndrome	3.43e-06	1.44e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IRS2—polycystic ovary syndrome	3.4e-06	1.43e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—LEP—polycystic ovary syndrome	3.38e-06	1.42e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IGF1—polycystic ovary syndrome	3.36e-06	1.41e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—AKT2—polycystic ovary syndrome	3.36e-06	1.41e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.35e-06	1.4e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.34e-06	1.4e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—LEP—polycystic ovary syndrome	3.33e-06	1.4e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.32e-06	1.39e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IGF1—polycystic ovary syndrome	3.31e-06	1.39e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—AKT2—polycystic ovary syndrome	3.31e-06	1.39e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.3e-06	1.38e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	3.28e-06	1.37e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IRS1—polycystic ovary syndrome	3.26e-06	1.37e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IRS1—polycystic ovary syndrome	3.23e-06	1.35e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.19e-06	1.34e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.15e-06	1.32e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—POMC—polycystic ovary syndrome	3.14e-06	1.32e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IRS2—polycystic ovary syndrome	3.14e-06	1.32e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—INS—polycystic ovary syndrome	3.12e-06	1.31e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PPARG—polycystic ovary syndrome	3.12e-06	1.31e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IRS1—polycystic ovary syndrome	3.12e-06	1.31e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—POMC—polycystic ovary syndrome	3.11e-06	1.3e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IRS1—polycystic ovary syndrome	3.1e-06	1.3e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—INS—polycystic ovary syndrome	3.09e-06	1.3e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IRS2—polycystic ovary syndrome	3.09e-06	1.29e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IRS2—polycystic ovary syndrome	3.08e-06	1.29e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—POMC—polycystic ovary syndrome	3.08e-06	1.29e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IRS2—polycystic ovary syndrome	3.07e-06	1.29e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—LEP—polycystic ovary syndrome	3.07e-06	1.29e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IRS2—polycystic ovary syndrome	3.06e-06	1.28e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—INS—polycystic ovary syndrome	3.06e-06	1.28e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IRS2—polycystic ovary syndrome	3.03e-06	1.27e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IRS2—polycystic ovary syndrome	3.02e-06	1.27e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—LEP—polycystic ovary syndrome	3.02e-06	1.27e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IGF1—polycystic ovary syndrome	3.02e-06	1.27e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—AKT2—polycystic ovary syndrome	3.02e-06	1.27e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IRS1—polycystic ovary syndrome	3.02e-06	1.27e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—LEP—polycystic ovary syndrome	3.01e-06	1.26e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—LEP—polycystic ovary syndrome	3e-06	1.26e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—POMC—polycystic ovary syndrome	3e-06	1.26e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—LEP—polycystic ovary syndrome	2.99e-06	1.26e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IGF1—polycystic ovary syndrome	2.99e-06	1.25e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—AKT2—polycystic ovary syndrome	2.99e-06	1.25e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—POMC—polycystic ovary syndrome	2.99e-06	1.25e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—INS—polycystic ovary syndrome	2.99e-06	1.25e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling by GPCR—IL6—polycystic ovary syndrome	2.98e-06	1.25e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling by GPCR—IL6—polycystic ovary syndrome	2.98e-06	1.25e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—INS—polycystic ovary syndrome	2.97e-06	1.25e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IRS1—polycystic ovary syndrome	2.97e-06	1.25e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—LEP—polycystic ovary syndrome	2.96e-06	1.24e-05	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—IL6—polycystic ovary syndrome	2.96e-06	1.24e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling by GPCR—IL6—polycystic ovary syndrome	2.96e-06	1.24e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—LEP—polycystic ovary syndrome	2.96e-06	1.24e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—POMC—polycystic ovary syndrome	2.91e-06	1.22e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling by GPCR—IL6—polycystic ovary syndrome	2.9e-06	1.22e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—INS—polycystic ovary syndrome	2.89e-06	1.21e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.89e-06	1.21e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.89e-06	1.21e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IGF1—polycystic ovary syndrome	2.87e-06	1.21e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—AKT2—polycystic ovary syndrome	2.87e-06	1.2e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.87e-06	1.2e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	2.86e-06	1.2e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—POMC—polycystic ovary syndrome	2.86e-06	1.2e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling by GPCR—IL6—polycystic ovary syndrome	2.85e-06	1.2e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—INS—polycystic ovary syndrome	2.84e-06	1.19e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.84e-06	1.19e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	2.82e-06	1.18e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling by GPCR—IL6—polycystic ovary syndrome	2.81e-06	1.18e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	2.81e-06	1.18e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—INS—polycystic ovary syndrome	2.81e-06	1.18e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IGF1—polycystic ovary syndrome	2.79e-06	1.17e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—AKT2—polycystic ovary syndrome	2.79e-06	1.17e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IGF1—polycystic ovary syndrome	2.75e-06	1.15e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—AKT2—polycystic ovary syndrome	2.75e-06	1.15e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	2.75e-06	1.15e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.74e-06	1.15e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IRS1—polycystic ovary syndrome	2.74e-06	1.15e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.73e-06	1.14e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling by GPCR—IL6—polycystic ovary syndrome	2.7e-06	1.13e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.69e-06	1.13e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.69e-06	1.13e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.68e-06	1.12e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IRS1—polycystic ovary syndrome	2.67e-06	1.12e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.65e-06	1.11e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IRS1—polycystic ovary syndrome	2.64e-06	1.11e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.64e-06	1.11e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—POMC—polycystic ovary syndrome	2.64e-06	1.11e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—INS—polycystic ovary syndrome	2.62e-06	1.1e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.61e-06	1.1e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—POMC—polycystic ovary syndrome	2.59e-06	1.09e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—POMC—polycystic ovary syndrome	2.59e-06	1.09e-05	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—IL6—polycystic ovary syndrome	2.58e-06	1.08e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—POMC—polycystic ovary syndrome	2.58e-06	1.08e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—INS—polycystic ovary syndrome	2.58e-06	1.08e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—INS—polycystic ovary syndrome	2.57e-06	1.08e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—POMC—polycystic ovary syndrome	2.57e-06	1.08e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling by GPCR—IL6—polycystic ovary syndrome	2.57e-06	1.08e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—INS—polycystic ovary syndrome	2.57e-06	1.08e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—INS—polycystic ovary syndrome	2.56e-06	1.07e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.55e-06	1.07e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—POMC—polycystic ovary syndrome	2.55e-06	1.07e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.55e-06	1.07e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—POMC—polycystic ovary syndrome	2.54e-06	1.07e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.54e-06	1.06e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—IL6—polycystic ovary syndrome	2.53e-06	1.06e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.53e-06	1.06e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—INS—polycystic ovary syndrome	2.53e-06	1.06e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.53e-06	1.06e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—INS—polycystic ovary syndrome	2.53e-06	1.06e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.5e-06	1.05e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.49e-06	1.05e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.49e-06	1.04e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.49e-06	1.04e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.48e-06	1.04e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.48e-06	1.04e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.48e-06	1.04e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IGF1—polycystic ovary syndrome	2.47e-06	1.04e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—AKT2—polycystic ovary syndrome	2.47e-06	1.04e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.45e-06	1.03e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.45e-06	1.03e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.45e-06	1.03e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.44e-06	1.02e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.44e-06	1.02e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.44e-06	1.02e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.41e-06	1.01e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.4e-06	1.01e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.37e-06	9.94e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.36e-06	9.92e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	2.36e-06	9.9e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.36e-06	9.88e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.35e-06	9.85e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	2.35e-06	9.84e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.33e-06	9.76e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.32e-06	9.73e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—IL6—polycystic ovary syndrome	2.31e-06	9.68e-06	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.3e-06	9.66e-06	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—IL6—polycystic ovary syndrome	2.3e-06	9.64e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—IL6—polycystic ovary syndrome	2.29e-06	9.6e-06	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—IL6—polycystic ovary syndrome	2.28e-06	9.58e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.27e-06	9.52e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.27e-06	9.51e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—IL6—polycystic ovary syndrome	2.21e-06	9.26e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—IL6—polycystic ovary syndrome	2.2e-06	9.22e-06	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.19e-06	9.2e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.16e-06	9.08e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.16e-06	9.04e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—IL6—polycystic ovary syndrome	2.14e-06	8.96e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—IL6—polycystic ovary syndrome	2.1e-06	8.82e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.97e-06	8.27e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.95e-06	8.2e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.94e-06	8.13e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.91e-06	8e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—IL6—polycystic ovary syndrome	1.9e-06	7.98e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—IL6—polycystic ovary syndrome	1.9e-06	7.96e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—IL6—polycystic ovary syndrome	1.89e-06	7.93e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.89e-06	7.91e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.88e-06	7.87e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.87e-06	7.86e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.87e-06	7.84e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.83e-06	7.66e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.8e-06	7.53e-06	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL6—polycystic ovary syndrome	1.76e-06	7.39e-06	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL6—polycystic ovary syndrome	1.76e-06	7.38e-06	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL6—polycystic ovary syndrome	1.75e-06	7.34e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.74e-06	7.28e-06	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL6—polycystic ovary syndrome	1.71e-06	7.18e-06	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL6—polycystic ovary syndrome	1.69e-06	7.07e-06	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL6—polycystic ovary syndrome	1.66e-06	6.97e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.66e-06	6.95e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.63e-06	6.83e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.63e-06	6.82e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.62e-06	6.8e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.62e-06	6.78e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.6e-06	6.71e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.6e-06	6.69e-06	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL6—polycystic ovary syndrome	1.59e-06	6.68e-06	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL6—polycystic ovary syndrome	1.52e-06	6.36e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL6—polycystic ovary syndrome	1.5e-06	6.28e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.48e-06	6.22e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL6—polycystic ovary syndrome	1.36e-06	5.72e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL6—polycystic ovary syndrome	1.35e-06	5.67e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL6—polycystic ovary syndrome	1.3e-06	5.47e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL6—polycystic ovary syndrome	1.3e-06	5.44e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL6—polycystic ovary syndrome	1.26e-06	5.29e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL6—polycystic ovary syndrome	1.24e-06	5.21e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL6—polycystic ovary syndrome	1.15e-06	4.8e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.13e-06	4.73e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL6—polycystic ovary syndrome	1.12e-06	4.72e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL6—polycystic ovary syndrome	1.12e-06	4.7e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL6—polycystic ovary syndrome	1.12e-06	4.69e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL6—polycystic ovary syndrome	1.11e-06	4.64e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL6—polycystic ovary syndrome	1.1e-06	4.63e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.03e-06	4.3e-06	CbGpPWpGaD
